“The Buzz” Show: Hoth Therapeutics (NASDAQ: HOTH) Production of HT-001 for Cancer Treatment | Financial Buzz

“The Buzz” Show: Hoth Therapeutics (NASDAQ: HOTH) Production of HT-001 for Cancer Treatment

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Hoth Therapeutics Skyrockets Amid Production of its HT-001 for Cancer Treatment

Hoth Therapeutics (NASDAQ: HOTH) shot up over 81% in premarket trading after announcing the production of its novel HT-001 for Cancer Treatment

The topical cancer treatment drug, HT-001, is designed for patients with mild to moderate rash and skin disorders associated with EGFR inhibitor therapy and is targeted to allow patients to achieve the best potential outcomes of EGFR therapy.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19.

For more information, please visit: Hoth Therapeutics, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!